Abstract:Objective To investigate the clinical effect of Huangzhi Capsule in the treatment of diabetic constipation and its effect on the plasma levels of the gastrointestinal hormones including substance P (SP), somatostatin (SS), and glucagon (GC). Methods A total of 60 patients with diabetic constipation who met the inclusion criteria were randomly divided into treatment group and control group, with 30 patients in each group. The patients in the control group were given basic treatment and mosapride dispersible tablets, and those in the treatment group were given basic treatment and Huangzhi Capsule. The course of treatment was 1 month for both groups. The two groups were observed in terms of the plasma levels of SP, SS, and GC, homeostasis model assessment of insulin resistance (HOMA- IR), traditional Chinese medicine (TCM) syndrome score, clinical outcome, and incidence rate of adverse reactions before and after treatment. Results After treatment, both groups had a significant increase in SP (P<0.05) and significant reductions in SS and GC (P<0.05), and there were significant differences in SP, SS, GC, and HOMA- IR between the two groups (P<0.05). After treatment, both groups had a significant reduction in TCM syndrome score (P<0.05), and the treatment group had a significantly greater reduction than the control group (P<0.05). There was a significant difference in the distribution of clinical outcomes between the two groups (P<0.05). There was a significant difference in the overall incidence rate of adverse reactions between the two groups (χ2=5.455, P=0.020). Conclusion Huangzhi Capsule combined with conventional hypoglycemic therapy can significantly alleviate clinical symptoms, regulate the abnormal secretion of gastrointestinal hormones, reduce blood glucose, and improve insulin resistance.